生存
SCLC 在接受确定性治疗后的生存取决于分期。局限期和扩散期的 5 年生存率大概分别为 12% 到 24% 以及 1% 到 5%。[53]Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1993;11:336-344.http://www.ncbi.nlm.nih.gov/pubmed/8381164?tool=bestpractice.com[54]Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054-3060.http://www.ncbi.nlm.nih.gov/pubmed/12118018?tool=bestpractice.com[55]Hanna N, Bunn PA, Jr., Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038-2043.http://jco.ascopubs.org/cgi/content/full/24/13/2038http://www.ncbi.nlm.nih.gov/pubmed/16648503?tool=bestpractice.com[56]Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-91.http://www.nejm.org/doi/full/10.1056/NEJMoa003034#t=articlehttp://www.ncbi.nlm.nih.gov/pubmed/11784874?tool=bestpractice.com
